Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysisCOVID-19로 병원에 입원한 환자의 바리시티닙(RECOVERY): 무작위, 통제, 공개 라벨, 플랫폼 시험 및 업데이트된 메타 분석Meta-Analysis Published on 2022-07-302022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 28-day mortality 95% CI age-adjusted rate ratio allocation Baricitinib benefit by mouth cause Corticosteroid Corticosteroids COVID-19 COVID-19 therapy death deaths died discharge eight enrolled evaluate Evidence hospital hospitalised Including Infection inhibitor Innovation intention-to-treat population ISRCTN Jak JAK inhibitor jak inhibitors janus Janus kinase Medical Research Council Meta-analysis mouth nine Non-COVID-19 once daily Open-label outcomes Patient Platform trial Primary outcome Proportional reduction randomisation randomised randomised controlled trial Randomised Evaluation Randomly randomly assigned patient rate ratio receive receiving recorded recovery RECOVERY trial reduce mortality reduced reduction in mortality Registered risk of death significantly Standard of care suggested thrombosis Tocilizumab Treatment Trial trials usual care usual care alone usual care group was done with COVID-19 [DOI] 10.1016/S0140-6736(22)01109-6 PMC 바로가기 [Article Type] Meta-Analysis
Impact of a phone call with a medical student/general practitioner team on morbidity of chronic patients during the first French COVID-19 lockdown (COVIQuest): a cluster randomised trialRandomized Controlled Trial Published on 2022-07-282022-10-04 Journal: BMJ Open [Category] 임상, [키워드] 95% CI Admission approach chronic cardiovascular Chronic diseases Cluster Contact control group COVID-19 CVD disease disorder eight evaluate French healthcare hospitalisation hospitalised Impact intervention group lack lockdown mental health morbidity older patient outcome Patient Preventive medicine primary care randomised controlled trial Randomised trial reduce reduced regions risk significantly statistical the patient usual care [DOI] 10.1136/bmjopen-2021-059464 PMC 바로가기 [Article Type] Randomized Controlled Trial
Are micro enemas administered with a squeeze tube and a 5 cm-long nozzle as good or better than micro enemas administered with a 10 cm-long catheter attached to a syringe in people with a recent spinal cord injury? A non-inferiority, crossover randomised controlled trial Research Published on 2022-07-272022-10-05 Journal: Spinal cord [Category] 임상, [키워드] 95% confidence interval Administered assigned blind blinded bowel Care Complete determine hospital non-inferiority non-inferiority margin objective outcome Primary outcome Quality of life randomised controlled trial Randomly reflected reported Result secondary secondary outcome Secondary outcomes sequence setting Spinal cord injury Treatment Treatment effectiveness were measured [DOI] 10.1038/s41393-022-00835-5 [Article Type] Research
Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)Favipiravir 및/또는 nitazoxanide: IMSS(FANTAZE)에서 치료를 받는 의료 종사자, 가족 구성원 및 환자를 대상으로 한 COVID-19 조기 치료에 대한 무작위, 이중 맹검, 2x2 설계, 위약 대조 시험Randomized Controlled Trial Published on 2022-07-222022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 1:1 2×2 design absence Admission antimicrobial Antimicrobials Antiviral effect antiviral therapy Antiviral treatment antivirals appear assigned Asymptomatic blinded to treatment combination therapy Comorbidities Comorbidity Controlled trial COVID-19 COVID-19 disease disease double-blind early disease early phase early treatment example Favipiravir followed by Gender Genetic genetic mutation Health high risk Hospitalization Hypothesis in some include individuals Infection Inflammatory Influenza intensive care investigator investigators later phase morbidity and mortality Mutation mutation rate nitazoxanide obesity older patient outcome pandemic participant patients treated pharmacokinetics phase phase IIa Placebo placebo-controlled placebo-controlled clinical trial placebo-controlled trial positive presence or absence Prevent Primary outcome progression protocol randomised randomised controlled trial Randomized receive replicates SARS-CoV-2 secondary Secondary outcomes security Sepsis severe disease smoking status Social Security Stratification symptomatic symptomatic COVID-19 Symptoms tested the disease therapy those with comorbidity Toxicity treatment allocation Trial upper respiratory tract Viral load virus [DOI] 10.1186/s13063-022-06533-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
A qualitative process analysis of daily contact testing as an alternative to self-isolation following close contact with a confirmed carrier of SARS-CoV-2SARS-CoV-2의 확인된 보균자와의 긴밀한 접촉 후 자가 격리의 대안으로 일일 접촉 테스트의 정성적 프로세스 분석Randomized Controlled Trial Published on 2022-07-182022-09-11 Journal: BMC Public Health [Category] COVID19(2023년), SARS, 임상, 치료기술, [키워드] absence alternative Analysis Attitude behavioural benefit chain Chain Reaction close contact conducted Contact contact with COVID-19 Daily DCT detect Factor feasible Flow Infection Interpretation interview Isolation Lateral Lateral flow device Lateral flow test participant PCR polymerase chain reaction Process process evaluation provided Qualitative randomised randomised controlled trial reaction reassurance reduce reducing reported risk risk of transmission SARS-CoV-2 SARS-CoV-2 transmission Self-isolation Seven study period Test Testing Trial were used [DOI] 10.1186/s12889-022-13800-x PMC 바로가기 [Article Type] Randomized Controlled Trial
Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial)Randomized Controlled Trial Published on 2022-07-092022-10-05 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI addition adverse events Anti-inflammatory anti-thrombotic properties Aspirin assigned benefit C-reactive protein clinical Clinical deterioration clinical trial Combination control group COVID-19 discharge group hospitalisation hospitalised patient improvement Infection interleukin-6 Mild Moderate COVID-19 no difference number observational study occurred Open-label Patient positive COVID-19 Prevent Primary outcome randomised randomised controlled trial Randomly receive Registered registry RT-PCR SARS-CoV-2 scale secondary outcome serum Serum IL-6 serum interleukin-6 level shown single-center Standard of care statin the study group therapy Treatment Trial troponin I WHO WHO ordinal scale WHO ordinal scale. [DOI] 10.1186/s12879-022-07570-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessmentdaclatasvir와 Sofosbuvir 및 COVID-19 환자의 결과: GRADE 평가를 통한 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-07-012022-09-11 Journal: Postgraduate medical journal [Category] 임상, [키워드] Admission certainty of evidence chance clinical clinical pharmacology clinical recovery clinically control group Controlled trial COVID-19 daclatasvir database databases death defined estimate evaluate the effect ICU ICU admission IMV inception increase in Infectious diseases intensive care intensive care unit internal medicine intervention group Invasive mechanical ventilation lower mortality Meta-analysis moderate Mortality mortality rate outcome Patient patients with COVID-19 performed Primary outcome randomised controlled trial reduce mortality rate reduced reported risk ratio risk ratios risk reduction RRs secondary outcome Secondary outcomes sofosbuvir sofosbuvir/daclatasvir Standard of care systematic literature search systematic review Virology [DOI] 10.1136/postgradmedj-2021-140287 PMC 바로가기 [Article Type] Meta-Analysis
Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)Randomized Controlled Trial Published on 2022-07-012022-10-04 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, [키워드] absence Adults adverse events adverse outcome alleviation of symptoms Analysis ARMS Blood Ciclesonide clinical Comorbidity control arm COVID-19 COVID-19 outpatient criteria Day death died Efficacy Endpoint European Medicines Agency Evidence Evolution Follow-up Hospitalization Hospitalized improvement Inhaled inhaled corticosteroid inhaled corticosteroids intent-to-treat interim analysis interquartile range involved median age median time men Open-label Other outcome Outpatient outpatients Oxygen therapy parameter participant patients with COVID-19 primary efficacy endpoint primary endpoint randomised controlled trial Randomized controlled trial Randomly reached reducing reported risk risk factor RT-PCR Safety Monitoring Board scale secondary sustained Symptom the WHO Treatment Trial women worsening [DOI] 10.1016/j.cmi.2022.02.031 PMC 바로가기 [Article Type] Randomized Controlled Trial
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females남성과 여성에서 ChAdOx1 nCoV-19(AZD1222) 백신에 대한 반응에 대한 탐색적 분석Article Published on 2022-07-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI Academy adjusted age and sex All participant All participants anti-SARS-CoV-2 anti-Spike IgG AstraZeneca AZD1222 both sexes Brazil Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 Chinese clinical Clinical research clinical trials Coalition Council COVID-19 COVID-19 vaccine COVID-19 vaccines defined dose doses Efficacy endpoints Engineering enrolled Evidence evidence of Exploratory analysis fatigue female females Fever first dose Follow-up foundation funding generate GMR greater headache humoral immune responses immunogenicity immunogenicity data immunological individual Innovation interaction term ISRCTN Linear model linear models log-transformed logistic regression models majority male males Medical Science NAAT nCoV network neutralisation assay NIHR no evidence of nucleic acid nucleic acid amplification nucleic acid amplification test Oxford participant Participants primary endpoint randomised randomised controlled trial reaction reactogenicity receive Registered Regression model reported SARS-COV-2 infection Science Sex Sex-differences shown single-blind South spike IgG Standard dose statistically significant difference Superior symptomatic SARS-CoV-2 infection systemic reaction Telle the primary endpoint titre trial participants vaccination Vaccine vaccine efficacy Vaccines Valley Volunteer [DOI] 10.1016/j.ebiom.2022.104128 PMC 바로가기 [Article Type] Article
Data-driven quality improvement program to prevent hospitalisation and improve care of people living with coronary heart disease: Protocol for a process evaluation관상 동맥 심장 질환 환자의 입원을 예방하고 치료를 개선하기 위한 데이터 기반 품질 개선 프로그램: 프로세스 평가 프로토콜Article Published on 2022-07-012022-09-11 Journal: Contemporary clinical trials [Category] 임상, [키워드] acceptability approach cardiovascular cardiovascular disease Care change clinical Cluster collected commitment complex components Controlled trial COVID-19 pandemic data data-driven determine Efficiency element ENhance feasibility finding heart disease hospitalisation hospitalisations identify implementation IMPROVE Intervention knowledge Mixed-method research multidimensional New offer patient data Prevent primary care Process process evaluation protocol Qualitative qualitative data Quality Quality improvement Quantitative data randomised controlled trial reduce registry Satisfaction secondary prevention utility [DOI] 10.1016/j.cct.2022.106794 PMC 바로가기 [Article Type] Article